Compare ABVE & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABVE | MOLN |
|---|---|---|
| Founded | 2019 | 2004 |
| Country | Canada | Switzerland |
| Employees | N/A | N/A |
| Industry | Packaged Foods | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.6M | 158.9M |
| IPO Year | N/A | 2021 |
| Metric | ABVE | MOLN |
|---|---|---|
| Price | $1.12 | $4.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 1.3M | 1.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $285.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $3.36 |
| 52 Week High | $6.56 | $5.36 |
| Indicator | ABVE | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 32.12 | 60.70 |
| Support Level | $0.90 | $3.50 |
| Resistance Level | $2.08 | $5.36 |
| Average True Range (ATR) | 0.12 | 0.14 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 16.62 | 59.34 |
Above Food Ingredients Inc is a differentiated, regenerative ingredient company. Its products are made with real nutritious, flavorful ingredients and delivered with transparency. Its vision is to create a healthier world one seed, one field, and one bite at a time. With a robust chain of custody of plant proteins, enabled by scaled operations and infrastructure in primary agriculture and processing, and proprietary seed development capabilities that leverage the power of artificial intelligence driven genomics. The company delivers nutritious foods to businesses and consumers with traceability and sustainability. Above Food's consumer products and brands are available in grocers across Canada and the United States.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.